Alok A Khorana1, Pamela B Mangu1, Jordan Berlin1, Anitra Engebretson1, Theodore S Hong1, Anirban Maitra1, Supriya G Mohile1, Matthew Mumber1, Richard Schulick1, Marc Shapiro1, Susan Urba1, Herbert J Zeh1, Matthew H G Katz1. 1. Alok A. Khorana and Marc Shapiro, Cleveland Clinic, Cleveland, OH; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Jordan Berlin, Vanderbilt University, Nashville, TN; Anitra Engebretson, Patient Representative, Portland, OR; Theodore S. Hong, Massachusetts General Hospital, Boston, MA; Anirban Maitra and Matthew H.G. Katz, The University of Texas MD Anderson Cancer Center, Houston, TX; Supriya G. Mohile, University of Rochester, Rochester, NY; Matthew Mumber, Harbin Clinic, Rome, GA; Richard Schulick, University of Colorado at Denver, Denver, CO; Susan Urba, University of Michigan, Ann Arbor, MI; and Herbert J. Zeh, University of Pittsburgh, Pittsburgh, PA.
Abstract
PURPOSE: To provide evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. METHODS: ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palliative care, and advocacy experts and conducted a systematic review of literature from January 2002 to June 2015. Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events. RESULTS: Nine randomized controlled trials met the systematic review criteria. RECOMMENDATIONS: A multiphase computed tomography scan of the abdomen and pelvis or magnetic resonance imaging should be performed for all patients to assess the anatomic relationships of the primary tumor and for the presence of intra-abdominal metastases. Baseline performance status, comorbidity profile, and goals of care should be evaluated and established. Primary surgical resection is recommended for all patients who have no metastases, appropriate performance and comorbidity profiles, and no radiographic interface between primary tumor and mesenteric vasculature. Preoperative therapy is recommended for patients who meet specific characteristics. All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of contraindications. Adjuvant chemoradiation may be offered to patients who did not receive preoperative therapy with microscopically positive margins (R1) after resection and/or who had node-positive disease after completion of 4 to 6 months of systemic adjuvant chemotherapy. Patients should have a full assessment of symptoms, psychological status, and social supports and should receive palliative care early. Patients who have completed treatment and have no evidence of disease should be monitored. Additional information is available at www.asco.org/guidelines/PCPC and www.asco.org/guidelineswiki.
PURPOSE: To provide evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. METHODS: ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palliative care, and advocacy experts and conducted a systematic review of literature from January 2002 to June 2015. Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events. RESULTS: Nine randomized controlled trials met the systematic review criteria. RECOMMENDATIONS: A multiphase computed tomography scan of the abdomen and pelvis or magnetic resonance imaging should be performed for all patients to assess the anatomic relationships of the primary tumor and for the presence of intra-abdominal metastases. Baseline performance status, comorbidity profile, and goals of care should be evaluated and established. Primary surgical resection is recommended for all patients who have no metastases, appropriate performance and comorbidity profiles, and no radiographic interface between primary tumor and mesenteric vasculature. Preoperative therapy is recommended for patients who meet specific characteristics. All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of contraindications. Adjuvant chemoradiation may be offered to patients who did not receive preoperative therapy with microscopically positive margins (R1) after resection and/or who had node-positive disease after completion of 4 to 6 months of systemic adjuvant chemotherapy. Patients should have a full assessment of symptoms, psychological status, and social supports and should receive palliative care early. Patients who have completed treatment and have no evidence of disease should be monitored. Additional information is available at www.asco.org/guidelines/PCPC and www.asco.org/guidelineswiki.
Authors: An Ngo-Huang; Nathan H Parker; Xuemei Wang; Maria Q B Petzel; David Fogelman; Keri L Schadler; Eduardo Bruera; Jason B Fleming; Jeffrey E Lee; Matthew H G Katz Journal: Langenbecks Arch Surg Date: 2017-07-15 Impact factor: 3.445
Authors: Davendra P S Sohal; Erin B Kennedy; Alok Khorana; Mehmet S Copur; Christopher H Crane; Ignacio Garrido-Laguna; Smitha Krishnamurthi; Cassadie Moravek; Eileen M O'Reilly; Philip A Philip; Ramesh K Ramanathan; Joseph T Ruggiero; Manish A Shah; Susan Urba; Hope E Uronis; Michelle W Lau; Daniel Laheru Journal: J Clin Oncol Date: 2018-05-23 Impact factor: 44.544
Authors: Jason W Denbo; Morgan L Bruno; Jordan M Cloyd; Laura Prakash; Jeffrey E Lee; Michael Kim; Christopher H Crane; Eugene J Koay; Sunil Krishnan; Prajnan Das; Bruce D Minsky; Gauri Varadhachary; Rachna Shroff; Robert Wolff; Milind Javle; Michael J Overman; David Fogelman; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz Journal: J Gastrointest Surg Date: 2016-10-11 Impact factor: 3.452
Authors: Justin A Barnes; Melissa L Ellis; Sharon Hwang; Joan Emarine; Patti Merwin; Gregory D Salinas; Benjamin L Musher Journal: J Gastrointest Cancer Date: 2019-03
Authors: Angelica Petrillo; Annalisa Pappalardo; Luca Pompella; Giuseppe Tirino; Filomena Calabrese; Maria Maddalena Laterza; Marianna Caterino; Anna Ventriglia; Michele Orditura; Giovanni Conzo; Carlo Molino; Fortunato Ciardiello; Maria Biglietto; Ferdinando De Vita Journal: Med Oncol Date: 2019-08-23 Impact factor: 3.064
Authors: Chunxia Du; Annacarolina da Silva; Vicente Morales-Oyarvide; Brian M Wolpin; Jonathan A Nowak; Andressa Dias Costa; Margaret M Kozak; Richard F Dunne; Douglas A Rubinson; Kimberly Perez; Yohei Masugi; Tsuyoshi Hamada; Lauren K Brais; Chen Yuan; Ana Babic; Matthew D Ducar; Aaron R Thorner; Andrew Aguirre; Matthew H Kulke; Kimmie Ng; Thomas E Clancy; Jennifer J Findeis-Hosey; Daniel T Chang; Jason L Hornick; Charles S Fuchs; Shuji Ogino; Albert C Koong; Aram F Hezel Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-28 Impact factor: 4.254